BIRC5 and ovarian cancer: To determine whether the transcription of the BIRC5 gene was actually required for the survival of the ovarian cancer cells, we treated them with YM155, a pharmacological inhibitor of survivin expression that blocks the promoter activity of the BIRC5 gene [17,18].